Étiquette : auto experimentation

Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users : A randomized, double-blind, controlled trial, Kerri A. Schoedel et al., 2018

Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users : A randomized, double-blind, controlled trial Kerri A. Schoedel, Isabella Szeto, Beatrice Setnik, Edward M. Sellers, Naama Levy-Cooperman, Catherine Mills, Tilden Etges, Kenneth Sommerville Epilepsy & Behavior, 2018, 88, 162–171. Doi : 10.1016/j.yebeh.2018.07.027   a b s t r a c t Rationale : Treatment with a highly purified oral solution of cannabidiol (CBD), derived from the plant Cannabis sativa L., demonstrated some evidence of central nervous system (CNS)-related adverse events in patients enrolled in phase 3 trials for treatment of childhood-onset epilepsy. Cannabidiol was categorized as a Schedule 1 substance by the United States Drug [...]

Lire la suite

Long-term effects of psychedelic drugs : A systematic review, Jacob S.Aday et al., 2020

Long-term effects of psychedelic drugs : A systematic review Jacob S.Adaya, Cayla M.Mitzkovitz, Emily K.Bloesch, Christopher C.Davoli, Alan K.Davis Neuroscience and Biobehavioral Reviews, 2020. Doi : 10.1016/j.neubiorev.2020.03.017   A B S T R A C T Research into the basic effects and therapeutic applications of psychedelic drugs has grown considerably in recent years. Yet, pressing questions remain regarding the substances’ lasting effects. Although individual studies have begun monitoring sustained changes, no study to-date has synthesized this information. Therefore, this systematic review aims to fill this important gap in the literature by synthesizing results from 34 contemporary experimental studies which included classic psychedelics, human subjects, and follow-up [...]

Lire la suite

Microdosing psychedelics : Motivations, subjective effects and harm reduction, Toby Lea et al., 2020

Microdosing psychedelics : Motivations, subjective effects and harm reduction Toby Lea, Nicole Amada, Henrik Jungaberl, Henrike Schecke, Michael Klein International Journal of Drug Policy, 2020, 75, 102600, 9 p. Doi : 10.1016/j.drugpo.2019.11.008 A B S T R A C T Background : In recent years there has been growing media attention on microdosing psychedelics (e.g., LSD, psilocybin). This refers to people routinely taking small doses of psychedelic substances to improve mental health and wellbeing, or to enhance cognitive performance. Research evidence is currently limited. This paper examines microdosing motivations, dosing practices, perceived short-term benefits, unwanted effects, and harm reduction practices. Methods : An international online survey [...]

Lire la suite

Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders, Toby Lea et al., 2020

Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders Toby Lea & Nicole Amada & Henrik Jungaberle & Henrike Schecke & Norbert Scherbaum & Michael Klein Psychopharmacology, 2020. Di : 10.1007/s00213-020-05477-0   Abstract Rationale : The regular consumption of very small doses of psychedelic drugs (known as microdosing) has been a source of growing media and community attention in recent years. However, there is currently limited clinical and social research evidence on the potential role of microdosing as therapies for mental and substance use disorders. Objectives : This paper examined subjective experiences of microdosing psychedelics to improve mental health or to cease [...]

Lire la suite

Microdosing psychedelics : Demographics, practices, and psychiatric comorbidities, Daniel Rosenbaum, et al., 2020

Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities Daniel Rosenbaum, Cory Weissman, Thomas Anderson, Rotem Petranker, Le-Anh Dinh-Williams, Katrina Hui and Emma Hapke Journal of Psychopharmacology, 2020, 1-11. doi.org/10.1177/0269881120908004   Abstract Rationale : Microdosing psychedelics – the practice of consuming small, sub-hallucinogenic doses of substances such as LSD or psilocybin – is gaining attention in popular media but remains poorly characterized. Contemporary studies of psychedelic microdosing have yet to report the basic psychiatric descriptors of psychedelic microdosers. Objectives : To examine the practices and demographics of a population of psychedelic microdosers – including their psychiatric diagnoses, prescription medications, and recreational substance use patterns – to develop a foundation [...]

Lire la suite

Role of the 5-HT2A Receptor in Self- and Other-Initiated Social Interaction in Lysergic Acid Diethylamide-Induced States : A Pharmacological fMRI Study, Katrin H. Preller et al., 2018

Role of the 5-HT2A Receptor in Self- and Other-Initiated Social Interaction in Lysergic Acid Diethylamide-Induced States : A Pharmacological fMRI Study Katrin H. Preller, Leonhard Schilbach, Thomas Pokorny, Jan Flemming, Erich Seifritz, and Franz X. Vollenweider The Journal of Neuroscience, 2018, 38, (14), 3603–3611. Doi : 10.1523/JNEUROSCI.1939-17.2018   Distortions of self-experience are critical symptoms of psychiatric disorders and have detrimental effects on social interactions. In light of the immense need for improved and targeted interventions for social impairments, it is important to better understand the neurochemical substrates of social interaction abilities. We therefore investigated the pharmacological and neural correlates of self- and other-initiated social interaction. In [...]

Lire la suite

Reported effects of psychedelic use on those with low well-being given various emotional states and social contexts, Natasha L. Mason et al., 2020,

Reported effects of psychedelic use on those with low well-being given various emotional states and social contexts Natasha L. Mason, Patrick C. Dolder and Kim P.C. Kuypers Drug Science, Policy and Law, 2020, Volume 6, 1–11. Doi : 10.1177/2050324519900068   Abstract Background : It has been suggested that the outcome of the psychedelic experience is dependent on set and setting. While scientific research into the therapeutic potential of psychedelics is growing, it is clear that in clinical populations an optimal set and setting will not always be attainable. It was aimed to assess under which emotional and environmental circumstances psychedelic users use psychedelics, and the outcome [...]

Lire la suite

The epidemiology of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption, Alan K. Davis et al., 2018

The epidemiology of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption Alan K. Davis, Joseph P. Barsuglia, Rafael Lancelotta, Robert M. Grant, and Elise Renn Journal of Psychopharmacology, 2018, 32, (7), 779–792. doi : 10.1177/0269881118769063   Abstract Background/Aim : 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a psychoactive compound found in several plants and in high concentrations in Bufo alvarius toad venom. Synthetic, Toad, and Plant-sourced 5-MeO-DMT are used for spiritual and recreational purposes and may have psychotherapeutic effects. However, the use of 5-MeO-DMT is not well understood. Therefore, we examined patterns of use, motivations for consumption, subjective effects, and potential benefits and consequences [...]

Lire la suite

Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study, Joseph Barsuglia et al., 2018

Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study Joseph Barsuglia, Alan K. Davis, Robert Palmer, Rafael Lancelotta, Austin-Marley Windham-Herman, Kristel Peterson, Martin Polanco, Robert Grant and Roland R. Griffiths Frontiers in Psychology, 2018, Vol 9, Article doi : 10.3389/fpsyg.2018.02459   5-MeO-DMT is a psychoactive substance found in high concentrations in the bufotoxin of the Colorado River Toad (Bufo alvarius). Emerging evidence suggests that vaporized 5-MeO-DMT may occasion mystical experiences of comparable intensity to those occasioned by more widely studied psychedelics such as psilocybin, but no empirical study has tested this hypothesis. Data was obtained from 20 individuals (Mage = [...]

Lire la suite